News Press Releases

2018/11/13 Reven News Press

MAD Cohort 1 Begins. MAD Cohort 1 begins seven-day dosing period.

2018/10/26 Reven News Press

SAD Cohort 5 Completed. SAD Cohort 5B doses subjects; Cohort 5 has finished.

2018/10/25 Reven News Press

SAD Cohort 5 Underway. SAD Cohort 5A doses subjects.

2018/10/05 Reven News Press

SAD Cohort 4 doses subjects; Cohort 4 has finished.

2018/09/21 Reven News Press

Marissa Mazzolini hired as Reven’s Medical Affairs Manager.

2018/09/21 Reven News Press

Reven announced today that Peter Pacult has been promoted to the position of Senior Director of Clinical Operations. Mr. Pacult’s role will focus on leading Reven’s clinical efforts. In addition, Dane Baruzini has been promoted to Senior Director of Commercial … Read More

2018/09/18 Reven News Press

SAD Cohort 3 doses subjects; Cohort 3 has finished.

2018/09/13 Reven News Press

SAD Cohort 2 doses subjects; Cohort 2 has finished.

2018/09/09 Reven News Press

SAD Cohort 1B doses subjects; Cohort 1 has finished.

2018/09/07 Reven News Press

Reven’s Phase 1 Clinical Trial Begins. Reven doses their first subjects (Cohort 1A) under open IND successfully kicking off Phase 1 Clinical Trial.

2018/09/03 Reven News Press

Izabela Kawczynski hired as Project Manager.

2018/08/31 Reven News Press

Reven selects a United States based CMO to handle drug GMP drug manufacturing and development.

2018/08/24 Reven News Press

Phase 1 protocol approved by the IRB giving Reven the green light for their Phase 1 study in San Antonio.

2018/07/06 Reven News Press

Reven Hires Vincent Vanderbent. Vincent Vanderbent hired as Reven’s Director of Corporate Communications.

2018/06/24 Reven News Press

Dr. Scott E. Woodman joins Reven’s Advisory Board   Click Here for CV – SCOTT_WOODMAN_CV_05_06_2018